A growing body of evidence suggests that bipolar disorder (BD) is a progressive disease according to clinical, biochemical and neuroimaging findings. This study reviewed the literature on the relationship between specific biomarkers and BD stages. Methods: A comprehensive literature search of MEDLINE and PubMed was conducted to identify studies in English and Portuguese using the keywords biomarker, neurotrophic factors, inflammation, oxidative stress, neuroprogression and staging models cross-referenced with bipolar disorder. Results: Morphometric studies of patients with BD found neuroanatomic abnormalities, such as ventricular enlargement, grey matter loss in the hippocampus and cerebellum, volume decreases in the prefrontal cortex and variations in the size of the amygdala. Other studies demonstrated that serum concentrations of neurotrophic factors, inflammatory mediators and oxidative stress may be used as BD biomarkers. Conclusions: The analysis of neurobiological changes associated with BD progression and activity may confirm the existence of BD biomarkers, which may be then included in staging models that will lead to improvements in treatment algorithms and more effective, individually tailored treatment regimens. Biomarkers may also be used to define early interventions to control disease progression.
Introduction
Bipolar disorder (BD) is a chronic, often serious psychiatric disease with a prevalence of 1% to 3% worldwide. 1 According to the World Health Organization, BD is the 12th most important cause of disability in the world, 2 and its morbidity and mortality are significant.
The reduction of mean life expectancy in BD is the result of the high rate of suicides, clearly associated with mood disorders, 3 and the increased prevalence of medical comorbidities, such as heart disease, diabetes, obesity and thyroid dysfunction, 4 found in over 80% of the patients. 5 A growing body of evidence suggests that BP is a progressive disease. [6] [7] [8] In 1899 Emil Kraepelin found that the intervals between mood episodes become successively shorter as the number of previous episodes increases. The same author described that, after a certain number of recurrences, episodes tend to occur more spontaneously, in contrast with initial episodes, which are usually triggered by psychosocial stress factors. 7, 9, 10 The increase of the number of mood episodes is associated with poorer responses to psychopharmacological treatment. 6, 8, [11] [12] [13] Moreover, changes in cognitive functions are more marked in advanced stages of the disease than in controls and in patients in the initial phases of this psychiatric disorder. 8 Recent studies also showed that cognitive dysfunction and functional deterioration persist even during the euthymic periods in the advanced stages of the disease. 14, 15 These clinical findings may be understood as a result of the neuroprogressive events that occur during the long course of BD. Neuroprogression involves a pathologic reorganization of the central nervous system (CNS) and is, therefore, associated with structural and functional changes of the neural substrate, which is involved in mood regulation. 8 Several studies have demonstrated that, in addition to the progression of clinical presentations, there are also biochemical and structural changes that confirm neuroprogression, as biological and neuroimaging patterns are different between the initial and the final phases of BD. 6, 16 The identification of neurobiological and neuroimaging changes associated with BD progression and activity is fundamental for the definition of biomarkers. Together with a clear understanding of the clinical course of the disease, the definition of biomarkers is fundamental for the development of staging models. BD staging models should be based on the progression from an at-risk to a more severe and refractory presentation and should classify patients according to different stages (I to IV).
A staging system should be used in clinical practice to select the most appropriate treatment and define early interventions that may control BD progression. 17 This study reviewed the literature about neuroimaging and neurobiological abnormalities in patients with BD as potential BD biomarkers. The analysis of neurobiological changes will focus on the role of neurotrophic factors, inflammatory mediators and oxidative stress in BD physiopathology, activity and progression, and the importance of BD staging will be reviewed.
Methods

A comprehensive literature search of MEDLINE
and PubMed was conducted to identify studies in English and Portuguese using the keywords biomarker, neurotrophic factors, inflammation, oxidative stress, neuroprogression and staging models cross-referenced with bipolar disorder. One hundred and fifty-two articles published from 1899 to 2013 were retrieved. Selection for inclusion was based primarily on the information found in the study abstracts. Moreover, the bibliographies of the selected articles were analyzed. Finally, studies published by experts in this area were also examined.
Two articles were excluded because they were written in a language other than English or Portuguese. Other studies were excluded because they did not investigate serum or imaging biomarkers and BD staging.
Results
Potential BD biomarkers
According to the definition adopted by the Biomarkers Definitions Working Group, a biomarker is a "characteristic objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention." 18 Biomarkers may be genes, proteins or other molecules, as well as morphological characteristics, associated with physiological or biological mechanisms. 19 They may be used for several purposes, such as defining prognosis and risk of developing a disease, monitoring response to treatment, establishing new therapeutic targets and elucidating unclear physiopathological processes. [19] [20] [21] In BD, biomarkers seem to be important to evaluate disease activity and progression associated with different moods (mood biomarkers), as well as to identify specific characteristics of the disease (trait biomarkers). 19, 22 Serum biomarkers have several advantages: easy collection, low cost, wide availability and possibility of use in large-scale studies.
Studies that investigated serum biomarkers of BD found that neurotrophins, inflammatory factors and mood episode and in patients not treated with lithium. 32 Therefore, the increase in amygdala volume, the focus of several studies, [33] [34] [35] [36] seems to be associated with treatment with lithium. 32, 37 Finally, numerous studies have documented the existence of white matter hyperintensities in individuals with BD. The presence of these abnormalities in deep white matter is about 2.5 times more likely to be found in individuals with BD than in healthy individuals. 38 Gulseren et al. reported that the number of total brain hyperintensities increases with the number of manic episodes. The same authors suggested that these lesions should be used as a biological BD marker because white matter hyperintensities are frequent findings in family members that do not have BD. 39
Potential serum BD biomarkers
Neurotrophic factors
Neurotrophic factors are a family of essential growth factors for neurogenesis and neuronal differentiation and survival. Neurotrophins also play an important role in synaptic plasticity and modulation of neuronal excitability. 40, 41 To this date, more than 50 neural growth factors have been identified. 42 Some other important neurotrophins are the neuronal growth factor, brain derived neurotrophin factor (BDNF), neurotrophin 3 (NT-3) and neurotrophin 4 (NT-4). 43 BDNF, the most abundant neurotrophin in the CNS, has a particularly high expression in the amygdala, hippocampus and prefrontal cortex, brain areas associated with the regulation of emotion and several cognitive functions, such as attention, memory and executive functioning. 19, 44, 45 The role of BDNF in BD pathogenesis has been extensively investigated. 41, 44 Recent studies suggested that BDNF might also be used as a biomarker of this mood disorder. Some of these studies showed evidence of promising properties of serum BDNF as a biomarker of BD state. The metaanalyses conducted by Lin and Fernandes et al. indicated that patients in the manic or depressive phase had lower blood concentrations of BDNF than healthy individuals, and that serum BDNF concentrations in euthymic patients were not significantly different from those found in controls. 45, 46 These results suggest that serum BDNF may be a potential biomarker of acute episodes. Additionally, preliminary studies by Fernandes et al. found that serum BDNF concentrations differentiate patients in a manic or depressive state from those in a euthymic phase, at a sensitivity of 90% and a specificity of 85%. 45 In contrast, a recent study found that laboratory measurements of serum BDNF concentrations may distinguish bipolar from unipolar depression at a oxidative stress are potential candidates. At the same time, neuroimaging studies found that certain changes in patients with BD might be potential BD biomarkers.
Potential BD neuroimaging biomarkers
The existence of changes in the brain structures of patients with BD has been largely reported in several studies. Morphometric studies of patients with BD found enlargements of the lateral and third ventricles. 23, 24 However, abnormal ventricular volumes are not evident from the onset of the disease and are often found only after several mood episodes. In fact, Strakowski et al.
reported that the volume of ventricles in patients with BD during the first manic episode was similar to that of healthy individuals, whereas enlarged ventricles were a significant finding only in multiple-episode patients.
Eight years after disease onset, lateral ventricles were 122% larger than at the time of the first episode. 24 The same study found that first-episode patients had a larger putamen than healthy individuals, although the difference from multiple-episode patients was not significant. The authors concluded that changes in putamen volume were not associated with BD progression. Nevertheless, studies should investigate whether this may be a neuroanatomic marker of BD traits or vulnerability, particularly if this finding is replicated in family members not affected by the disease. 24 Other studies found a progressive decline in hippocampal and cerebellar gray matter density in people with BD. As the volume of these structures is smaller in patients with multiple mood episodes than in first-episode patients, the decline in hippocampal and cerebellar gray matter density may be a marker of disease progression. 25 In the same line of investigation, Brambilla et al. found an inverse correlation between cerebellar vermis volume and number of BD episodes. 26 Several studies also found a reduction in the volume of some areas of the prefrontal cortex. 23, 27 However, the results of several other studies do not always confirm it. 19 López-Larson et al. found that although the volume of the prefrontal lobe of patients with BD is similar to that of healthy individuals, there are differences in volume of gray matter in both the right and left prefrontal cortex.
Their findings also showed that disease duration may be correlated with a smaller volume of gray matter in the left inferior prefrontal cortex. 28 In addition to the neurostructural abnormalities mentioned above, an increase in the size of the amygdala was also found in adults with BD. 29 However, studies with children and adolescents with BD have found a decline in amygdala volume. 30, 31 According to Hallahan et al., the size of the amygdala is smaller in patients after the first system in response to noxious stimuli. In the CNS, cytokines act in specific pathways and are associated with mood control, energy and activity. 69 Moreover, inflammatory factors interact with the neuroendocrine system, specifically the hypothalamus-hypophysisadrenal axis, the autonomous nervous system and the system of neurotransmitters, which includes dopamine, serotonin and glutamate. 69, 70 In the last years, a growing number of publications have suggested that the immunoinflammatory system may be involved in BD physiopathology. In fact, recent studies with patients with BD confirmed the presence of chronic inflammation in this mood disorder. 5 In general, mood episodes may be classified as proinflammatory states. 43 Brietzke et al. found that patients with BD in a manic state had higher inteleukin-2 (IL-2), IL-4 and IL-6 concentrations than controls, whereas in patients with BD in a depressive state, only the proinflammatory cytokine IL-6 was elevated. The same authors found that, during euthymic states, only the IL-4 levels were elevated. 71 These findings suggest that mania and depression, at a lower grade, are associated with a proinflammatory state. 72 In addition to the changes in inflammatory cytokines described above, moderately elevated levels of C-reactive protein are found during manic episodes. 74 Increased concentrations of proinflammatory cytokines, found in patients with BD, may indicate an association with high rates of medical comorbidities, particular heart disease, 5 as these inflammatory changes may be risk factors for the development of obesity, hypertension, diabetes and atherosclerosis. 75 These findings stress the importance of medical evaluations and physical diagnostic accuracy of 88% for values equal to or lower than 0.26 pg/mL. The authors compared plasma BDNF concentrations of patients with BD in a depressive state with patients with unipolar depression, and found that the first group expressed lower levels of BDNF. 47 Clinically, the difference between bipolar and unipolar depression remains challenging, 47 as the BD diagnosis can only be made if the patient has at least one manic or hypomanic episode. 48 Therefore, blood BDNF concentrations may be an important element to establish the differential diagnosis between these diseases. 47 Other studies suggest that BDNF may be a biomarker of disease progression and severity. In this sense, BDNF values are inversely correlated with severity of symptoms of patients with BD. 49, 50 To explore the potential of blood BDNF to discriminate advanced and initial BD states, Kapczinski et al. raised the hypothesis that serum BDNF concentrations may discriminate patients with BD for less than 3 years from patients that have had it for over 10 years, 45 at a sensitivity of 100%, specificity of 88% and accuracy of 95% for values equal to or lower than 0.62 pg/mL. 51 Another potential application of serum BDNF concentrations is the prediction of response to treatment and the control of pharmacological efficacy. In fact, Tramontina et al. found that there is a normalization of blood BDNF levels after appropriate treatment of acute mania. 52, 53 Rybakowski and Suwalska, in turn, found that patients with an excellent response to lithium had higher plasma BDNF levels than patients refractory to treatment with this drug. 54 To clarify the mechanisms that underlie the decline of BDNF levels in patients with BD, several studies have investigated the existence of polymorphisms in the bdnf gene. One of the most frequently investigated polymorphisms is a methionine substitution for valine at codon 66 (val66met) in the region of the promoter of the bdnf gene. However , studies found divergent results when investigating the association between the val66met polymorphism and BD development. [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] Differences in results may indicate that genetic alterations in different ethnic groups, races or populations may confer different levels of susceptibility to BD development. 41 In addition to BDNF, other neurotrophins are also abnormal in the plasma of patients with BD. Patients with BD have higher serum NT-3 concentrations during mood episodes than euthymic patients or healthy individuals. 43, 50, 66, 67 Neurotrophin 4/5 (NT-4/5) seems to be persistently higher in the blood of patients with BD, regardless of their mood state. 43, 68 
Inflammatory factors
Inflammatory factors, also known as cytokines, are BD during a manic episode. 43, 86 In contrast, other studies found a decrease in SOD activity during all BD phases, 43 whereas Raffa et al. did not find any differences in SOD levels between patients with BD and healthy individuals. 43, 87 One of the consequences of oxidative stress is DNA damage, and studies with patients with BD have shown an increase in the frequency of DNA damage. 19, 43, 88 Andreazza et al. described a positive correlation between manic and depressive symptom severity and increased DNA damage. 88 At the same time, DNA damage has also been associated with reductions in telomere length in lymphocytes of individuals with BD. 19, 89 According to Saretzki and Von-Zglinicki, telomere shortening may be indicative of cumulative oxidative stress. 90 Moreover, a study with patients with BD concluded that the number of shortened telomeres and mean telomere length are associated with number of depressive episodes along life, but not with type of disease. 6, 89 Telomere shortening physiologically occurs after each cell division as part of normal ageing.
However, telomere shortening found in individuals with BD seems to be indicative of ageing acceleration in about 10 years. These data may explain the association between BD and early medical comorbidities associated with ageing. 91 Another element to support the role of oxidative stress in BD is the evidence that antioxidant compounds, such as N-acetylcystein (NAC) are beneficial in the treatment of BD, according to several studies. NAC, a glutathione precursor, efficiently reduces depressive symptoms in patients with BD and improves their functioning and quality of life. 92, 93 Treatment effects of mood stabilizers seem to be associated with their action upon oxidative stress pathways. 19 Patients with BD treated with lithium have a significant reduction of TBARS concentrations and of the SOD/CAT ratio, 19, 89 whereas healthy individuals exposed to lithium do not have the same changes. 19, 94 These findings suggest that lithium has an antioxidant effect favorable for the treatment of BD.
To evaluate systemic toxicity in BD, Kapczinski et al. compared the concentrations of several markers in patients with BD, healthy individuals and patients with sepsis. One of their notable findings was the impressive magnitude of oxidative damage during acute BD episodes, as high as the level seen in patients with sepsis in some cases. 42, 95 control of patients with BD, as well as of the definition of adequate treatments to reduce early deaths associated with BD. Comorbidities seem to be not only a consequence of treatment and life style characteristic of individuals with BD, but also a symptom of this psychiatric disorder. 5 In fact, medical burden is part of the early stages of BD. 5 Over 70% of young individuals with BD are estimated to need treatment for chronic medical conditions. 76 Middle-aged individuals with BD, in contrast, develop heart disease and hypertension at a younger age than adults without BD. 77 Therefore, medical burden should be included in BD staging.
Oxidative stress
Oxidative stress is the result of imbalance between oxidant and antioxidant enzymes, which usually results in cell damage. Lower antioxidant levels and an increased production of pro-oxidant agents give rise to oxidative stress, which leads to changes in macromolecules, such as lipid, proteins, carbohydrates and DNA. 43, 78 The CNS is particularly vulnerable to oxidative lesions, because the brain uses great amounts of oxygen, which promotes the formation of oxygen free radicals and oxygen reactive species. Moreover, the CNS has a limited antioxidant capacity, and glutathione is the main antioxidant in the brain. 43, 79 The antioxidant system is composed of an enzyme, such as superoxide dismutase (SOD), catalase and glutathione peroxidase, and a non-enzyme component, such as glutathione. 43 The role of oxidative stress in the physiopathology of BD has been investigated in several studies, which consistently reported changes in antioxidant enzymes, lipid peroxidation and levels of nitric oxide (NO), an important marker of oxidative stress. 19, 80, 81 The meta-analysis conducted by Andreazza et al. concluded that some of the oxidative stress markers are elevated in plasma or blood cells of individuals with BD, particularly NO and thiobarbituric acid reactive substances (TBARS), markers of lipid peroxidation. 80 The analysis of blood TBARS concentrations in patients with BD revealed that they are elevated during all stages of BD. 82 These results suggest that lipid damage occurs all along the course of this mood disorder. 80 Therefore, these findings suggest that the levels of TBARS may be used as biomarkers of BD progression if future studies confirm that they increase with disease duration. In addition to TBARS, NO concentrations are also elevated in BD, regardless of mood state. 19, 83 Andreazza et al.
found that there are other oxidative stress markers, such as 3-nitrotyrosine (3-NT), that are elevated in the initial stages of BD. 84 However, the results of studies about the antioxidant enzyme system are often discordant.
with BD may experience a phase characterized by symptom persistence and resistance to treatment, without interepisode symptom remission (stage 4) 17, 99 ( Table 1 ). (Table 1) . 17, 100 The staging models described by Berk et al. and are fundamental for neuroprotection. 101 Therefore, the treatment during the initial stages of the disease should primarily focus on neuroprotective strategies, but treatment during more advanced stages should be palliative and rehabilitative to control the consequences of disease progression. 99 The importance assigned to neuroprotective strategies may take psychiatry to a new era of preventive psychopharmacology. 43
The importance of BD staging
Staging is a widely used tool in Medicine, particularly in cancer and heart disease, and is the basis for the choice of adequate treatment and the definition of a prognosis. 96 However, only recently have the first models of staging of psychiatric disorders been developed. 97 To build staging models, the course of the disease should be predictable along time, 96 
Finally, individuals
Berk et al. 98 Kapczinski et al. 73 BDNF = brain-derived neurotrophic factor, IL = interleukin, TNF-α = tumor necrosis factor alpha, 3-NT = 3-nitrotyrsosine.
Conclusions
Although 
